Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Jun 24

PMID 35741170

Authors

Uwe Bieri

Lorenz Buser

Marian Severin Wettstein

Daniel Eberli

Karim Saba

Holger Moch

Thomas Hermanns

Cedric Poyet

Affiliations

Soon will be listed here.

Abstract

To evaluate the prognostic value of a modified Immunoscore (mIS) in a cohort of bladder cancer (BC) patients undergoing radical cystectomy (RC), two tissue microarrays of 159 BC patients were immunohistochemically stained for CD3/CD8/FOXP3 and CD45RO to detect Tumor-Infiltrating Lymphocytes (TIL). To predict progression free survival (PFS) and cancer specific survival (CSS), a predictive model cumulatively incorporating all four components was constructed and labeled as mIS. Patients were stratified into two risk groups; "high mIS/favorable risk" and "low mIS/unfavorable risk". Kaplan-Meier analysis was used to test mIS within each American Joint Committee on Cancer (AJCC) stage group for BC. In a univariable cox regression analysis all single components used for mIS, showed a significant association with CSS. Patients with high mIS (all components) in the AJCC stage IIIa group additionally showed a significantly longer PFS (Hazard Ratio (HR): 2.7; = 0.008) and CSS (HR: 3.5; = 0.006) as compared to patients with low mIS. mIS is of prognostic value in BC patients undergoing RC and was able to stratify patients within AJCC stage IIIa and might thus serve as a prognostic marker to guide risk-adapted treatment or follow-up strategies after RC.

Citing Articles

CD8+ Cell Density Gradient across the Tumor Epithelium-Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy.

Drachneris J, Rasmusson A, Morkunas M, Fabijonavicius M, Cekauskas A, Jankevicius F Cancers (Basel). 2023; 15(4).

PMID: 36831546 PMC: 9954554. DOI: 10.3390/cancers15041205.

Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study.

Bieri U, Enderlin D, Buser L, Wettstein M, Eberli D, Moch H Front Oncol. 2022; 12:964672.

PMID: 36212478 PMC: 9539272. DOI: 10.3389/fonc.2022.964672.

References

Ingels A, Sanchez Salas R, Ravery V, Fromont-Hankard G, Validire P, Patard J . T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. Ecancermedicalscience. 2014; 8:486. PMC: 4263522. DOI: 10.3332/ecancer.2014.486. View

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

Sharma P, Shen Y, Wen S, Yamada S, Jungbluth A, Gnjatic S . CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007; 104(10):3967-72. PMC: 1820692. DOI: 10.1073/pnas.0611618104. View

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

Ohue Y, Nishikawa H . Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci. 2019; 110(7):2080-2089. PMC: 6609813. DOI: 10.1111/cas.14069. View

Pierconti F, Martini M, Fiorentino V, Cenci T, Capodimonti S, Straccia P . The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?. Urol Oncol. 2020; 39(2):131.e17-131.e21. DOI: 10.1016/j.urolonc.2020.06.018. View

Galon J, Angell H, Bedognetti D, Marincola F . The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013; 39(1):11-26. DOI: 10.1016/j.immuni.2013.07.008. View

Kamat A, Bellmunt J, Galsky M, Konety B, Lamm D, Langham D . Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017; 5(1):68. PMC: 5557323. DOI: 10.1186/s40425-017-0271-0. View

Pierconti F, Martini M, Cenci T, Fiorentino V, Di Gianfrancesco L, Ragonese M . The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma. Urol Oncol. 2021; 40(3):108.e19-108.e25. DOI: 10.1016/j.urolonc.2021.11.013. View

10.

Redelman-Sidi G, Glickman M, Bochner B . The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014; 11(3):153-62. DOI: 10.1038/nrurol.2014.15. View

11.

Loughrey M, Bankhead P, Coleman H, Hagan R, Craig S, McCorry A . Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. Histopathology. 2018; 73(2):327-338. DOI: 10.1111/his.13516. View

12.

Kamat A, Gee J, Dinney C, Grossman H, Swanson D, Millikan R . The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006; 175(3 Pt 1):881-5. DOI: 10.1016/S0022-5347(05)00423-4. View

13.

Zhang X, Yang J, Du L, Zhou Y, Li K . The prognostic value of Immunoscore in patients with cancer: A pooled analysis of 10,328 patients. Int J Biol Markers. 2020; 35(3):3-13. DOI: 10.1177/1724600820927409. View

14.

Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4):1021-9. DOI: 10.1016/j.juro.2016.06.049. View

15.

Galon J, Pages F, Marincola F, Angell H, Thurin M, Lugli A . Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012; 10:205. PMC: 3554496. DOI: 10.1186/1479-5876-10-205. View

16.

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

17.

Kamat A, Hegarty P, Gee J, Clark P, Svatek R, Hegarty N . ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2012; 63(1):4-15. DOI: 10.1016/j.eururo.2012.09.057. View

18.

Roudnicky F, Poyet C, Buser L, Saba K, Wild P, Otto V . Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. Am J Pathol. 2020; 190(9):1960-1970. DOI: 10.1016/j.ajpath.2020.05.020. View

19.

Mathieu R, Lucca I, Roupret M, Briganti A, Shariat S . The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016; 13(8):471-9. DOI: 10.1038/nrurol.2016.126. View

20.

Yu A, Mansure J, Solanki S, Siemens D, Koti M, Dias A . Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One. 2018; 13(10):e0205746. PMC: 6181418. DOI: 10.1371/journal.pone.0205746. View